Clinical Trials

Breast Neoplasms

NCT03356860 2024-11-20

B-IMMUNE

Phase 1/2 Completed

57 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03013504 2024-11-06

TROIKA

503 enrolled

Breast Neoplasms

NCT03355157 2024-10-01

PADMA

Phase 4 Completed

130 enrolled

Breast Neoplasms, Patient Acceptance of Health Care

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT00630032 2024-02-21

TavIx

762 enrolled 14 charts

Breast Neoplasms

NCT00066443 2023-08-04

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Phase 1/2 Completed

93 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00841828 2023-03-31

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

102 enrolled 10 charts

Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

47 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00129922 2023-03-06

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

1,289 enrolled

Breast Neoplasms

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

150 enrolled

Breast Neoplasms

NCT02549677 2022-10-27

ELEGANT

Phase 4 Completed

294 enrolled

Breast Neoplasms

NCT00087178 2022-08-11

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

2,722 enrolled 14 charts

Breast Neoplasms

NCT03556358 2022-01-14

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

809 enrolled 14 charts

Breast Neoplasms

NCT00193206 2021-11-23

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

123 enrolled 8 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00193050 2021-10-26

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

110 enrolled 8 charts

Breast Neoplasms

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

105 enrolled 17 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02742051 2021-09-23

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

40 enrolled

Breast Neoplasms

NCT01593020 2021-09-22

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

54 enrolled 10 charts

Breast Neoplasms

NCT03289819 2021-04-08

NIB

53 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02685059 2021-02-15

GeparNuevo

174 enrolled

Breast Neoplasms

NCT01690702 2021-02-02

GAIN-2

2,886 enrolled

Breast Neoplasms

NCT04659551 2020-12-09

GIADA

43 enrolled

Breast Neoplasms

NCT00309569 2020-10-14

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

429 enrolled

Breast Neoplasms

NCT01026116 2020-05-12

A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old

521 enrolled

Breast Neoplasms

NCT00002542 2020-04-01

Tamoxifen in Treating Women With High-Risk Breast Cancer

672 enrolled

Breast Neoplasms

NCT00002866 2020-04-01

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

50 enrolled

Breast Neoplasms, Neutropenia

NCT02789332 2020-03-17

GeparOla

107 enrolled

Kenny-Caffey syndrome, Type 1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04224922 2020-01-18

Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

63 enrolled

Breast Neoplasms

NCT02628613 2019-11-01

Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations

91 enrolled

Breast Neoplasms

NCT02115204 2019-10-03

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

2,011 enrolled

Breast Neoplasms

NCT00776724 2019-05-06

TaiNAC

166 enrolled

Breast Neoplasms

NCT00513292 2019-01-23

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

280 enrolled 12 charts

Breast Neoplasms

NCT00559845 2018-04-09

A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

56 enrolled 10 charts

Breast Neoplasms

NCT00689156 2018-04-05

READ

2,015 enrolled

Breast Neoplasms

NCT01624441 2018-03-30

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

40 enrolled

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

596 enrolled 31 charts 1 FDA

Breast Neoplasms

NCT00722293 2017-11-13

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

111 enrolled

BreastGynecologicSarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

NCT02980965 2017-11-13

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

249 enrolled

Breast Neoplasms

NCT02001506 2017-08-29

Neo-shorter

250 enrolled

Breast Neoplasms

NCT02365805 2017-03-13

BERNAQ

30 enrolled

Breast Neoplasms

NCT00379015 2016-09-28

Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer

38 enrolled

Breast Neoplasms

NCT02846428 2016-07-27

To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer

182 enrolled

Breast Neoplasms

NCT00429299 2016-03-22

CHERLOB

121 enrolled 16 charts

Breast Neoplasms

NCT00322374 2016-03-10

Phase I Combination w/ Epirubicin

42 enrolled 24 charts

Breast Neoplasms

NCT00544232 2016-02-15

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

720 enrolled

Breast Neoplasms

NCT00753207 2016-02-15

Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30

10 enrolled

Breast Neoplasms

NCT00540800 2016-01-14

BREAST-10

139 enrolled

Breast Neoplasms

NCT00617370 2015-12-23

Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

Phase NA Completed

38 enrolled